AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 39442667
Drug: STAND (Motivational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STAND (Motivational Interviewing-Enhanced Behavior Therapy)
Trial: 39442958
Drug: Intensive adjuvant
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive adjuvant treatment (arm A): four cycles of docetaxel, epirubicin, and cyclophosphamide followed by four cycles of gemcitabine and cisplatin (n=166)
Trial: 39442958
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (arm B): four cycles of epirubicin and cyclophosphamide followed by four cycles of docetaxel (n=170)
Trial: 39442958
Drug: Intensive adjuvant
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive adjuvant treatment (arm A)
Trial: 39442958
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (arm B)
Trial: 39443081
Drug: Rifaximin 400
RxNorm normalized name: Rifaximin 400 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin 400 mg twice daily for 8 weeks
Trial: 39443403
Drug: Isavuconazole as
RxNorm normalized name: isavuconazole
DrugBank: Isavuconazole (DB11633)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isavuconazole as primary therapy
Trial: 39443403
Drug: Isavuconazole as
RxNorm normalized name: isavuconazole
DrugBank: Isavuconazole (DB11633)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isavuconazole as salvage therapy
Trial: 39443446
Drug: Ductal lavage
RxNorm normalized name: lovage oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ductal lavage with triamcinolone acetonide and antibiotics followed by observation (DL-OBS)
Trial: 39443527
Drug: LPVr (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPVr (400 mg/100 mg twice daily)
Trial: 39443527
Drug: LPVr +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPVr + TLM (10 mg once daily)
Trial: 39443527
Drug: LPVr +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPVr + ATV (20 mg once daily)
Trial: 39443659
Drug: Amiodarone (therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone (therapeutic doses)
Trial: 39443721
Drug: Accelerated intermittent
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated intermittent theta burst stimulation (aiTBS) during the acute phase (8 times daily for up to 10 days)
Trial: 39443721
Drug: Accelerated intermittent
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated intermittent theta burst stimulation (aiTBS) during the tapering phase (2 treatment days per week for 2 weeks, followed by 1 treatment day per week for 2 weeks)
Trial: 39443927
Drug: Lidocaine 1%
RxNorm normalized name: LIDOCAINE 1% LOTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 1% (0.3 mL)
Trial: 39443927
Drug: Papaverine HCl
RxNorm normalized name: papaverine HCl
DrugBank: Papaverine (DB01113)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Papaverine HCl 10 mg/mL (0.3 mL)
Trial: 39443954
Drug: Ivabradine (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivabradine (standard treatment for sepsis plus enteral ivabradine)
Trial: 39443954
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment group (GS)
Trial: 39443991
Drug: Blood biomarkers
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood biomarkers (surfactant protein-D, serine protease inhibitor A7, MMP-9)
Trial: 39443991
Drug: Blood biomarkers
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood biomarkers (CC motif chemokine 11, vascular cell adhesion protein-1, adiponectin, carcinoembryonic antigen, MMP-9)
Trial: 39444037
Drug: AL002 (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AL002 (single intravenous infusion)
Trial: 39444037
Drug: AL002 (weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AL002 (weekly intravenous injections for 4 weeks in cynomolgus monkeys)
Trial: 39444039
Drug: Anthracycline based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthracycline based chemotherapy
Trial: 39444039
Drug: Ongoing clinical
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ongoing clinical trials combining chemotherapy with immune checkpoint inhibitors
Trial: 39444052
Drug: Prasugrel monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel monotherapy (3.75 mg/day)
Trial: 39444052
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (DAPT) with prasugrel and aspirin
Trial: 39444052
Drug: No-aspirin group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-aspirin group
Trial: 39444571
Drug: Bovine milk-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine milk-based infant formula with added bovine MFGM (5 g/L) for 60 days
Trial: 39445319
Drug: Tildrakizumab 100
RxNorm normalized name: tildrakizumab 100 mg/mL subcutaneous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tildrakizumab 100 mg at baseline, Week 4, and every 12 weeks thereafter to Week 52, with final assessment at Week 64.
Trial: 39445319
Drug: Tildrakizumab treatment
RxNorm normalized name: Tildrakizumab
DrugBank: Tildrakizumab (DB14004)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tildrakizumab treatment
Trial: 39445439
Drug: combination results
RxNorm normalized name: omega-3 acid ethyl esters (USP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination results
Trial: 39445439
Drug: combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination of neomer and ctDNA mutation-based results
Trial: 39445609
Drug: perindopril/amlodipine 4/5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: perindopril/amlodipine 4/5 mg
Trial: 39445609
Drug: perindopril/amlodipine/indapamide 4/5/1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: perindopril/amlodipine/indapamide 4/5/1.25 mg
Trial: 39446087
Drug: UGN-102 (mitomycin),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UGN-102 (mitomycin), 6 weekly intravesical instillations
Trial: 39446327
Drug: RT twice
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT twice daily to a dosage of 45 Gy for 3 weeks
Trial: 39446327
Drug: RT once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT once daily to a dosage of 70 Gy for 7 weeks
Trial: 39446365
Drug: Intravenous nivolumab,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nivolumab, 3 mg/kg, every 2 weeks and ipilimumab, 1 mg/kg, every 6 weeks until disease progression, intolerable adverse events, or a maximum duration of 2 years.
Trial: 39446377
Drug: Overall targeted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall targeted therapy cohort
Trial: 39446605
Drug: HLX07 monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HLX07 monotherapy (1,000 mg IV Q2W)
Trial: 39446605
Drug: HLX07 combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HLX07 combined with serplulimab (200 mg IV day 1) and cisplatin (50 mg/m2)
Trial: 39446648
Drug: internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: internet-based cognitive behavioral sex therapy (iCBST)
Trial: 39446648
Drug: internet-based mindfulness-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: internet-based mindfulness-based sex therapy (iMBST)
Trial: 39446736
Drug: Standard sacrospinous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard sacrospinous ligament suspension with sutures (SSLS)
Trial: 39446746
Drug: COVID-19 treatment
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COVID-19 treatment disruptions
Trial: 39447049
Drug: Performance of
RxNorm normalized name: Perform
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Performance of instrumental activities of daily living (Lawton and Brody scale)
Trial: 39447049
Drug: Dependence on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dependence on activities of daily living (Barthel scale)
Trial: 39447053
Drug: F2 antigen
RxNorm normalized name: TRICOPHYTON ANTIGEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F2 antigen or F2 antigen plus AS01 adjuvant (third dose)
Trial: 39447517
Drug: SG001 240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SG001 240 mg every two weeks for 24 months or until disease progression, intolerable toxicities, or other study discontinuation criteria were met.
Trial: 39447587
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of asthma medication in adolescents with severe symptoms
Trial: 39447716
Drug: Intra-aortic balloon
RxNorm normalized name: somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra-aortic balloon pumping (IABP) as an adjunct to veno-arterial (V-A) ECMO
Trial: 39447871
Drug: Port Delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Port Delivery System with ranibizumab (100 mg/mL) Q24W
Trial: 39447871
Drug: Monthly intravitreal
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly intravitreal ranibizumab (0.5 mg)
Trial: 39448077
Drug: Bilateral iTBS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral iTBS at 0-min intervals (once-daily)
Trial: 39448218
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg micronised progesterone (mP) per day in continuous combination with 1 mg oestradiol
Trial: 39448218
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg norethisterone acetate (NETA) per day in continuous combination with 1 mg oestradiol
Trial: 39448218
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg micronised progesterone (mP) with 1 mg oestradiol
Trial: 39448350
Drug: Avelumab first-line
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab first-line maintenance treatment
Trial: 39448350
Drug: Avelumab first-line
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab first-line maintenance treatment followed by second-line enfortumab vedotin
Trial: 39448350
Drug: Avelumab first-line
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab first-line maintenance treatment followed by platinum-based chemotherapy (PBC)
Trial: 39448966
Drug: Spartalizumab (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spartalizumab (300 mg every 3 weeks) with platinum-doublet chemotherapy (PDC)
Trial: 39448986
Drug: tixagevimab/cilgavimab (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tixagevimab/cilgavimab (300 mg)
Trial: 39448999
Drug: Six-monthly PrEP
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Six-monthly PrEP dispensing with interim HIV self-testing (HIVST)
Trial: 39448999
Drug: Standard-of-care three-monthly
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care three-monthly PrEP dispensing with clinic-based HIV testing
Trial: 39449056
Drug: Functional exercise
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional exercise program (45-minute sessions, twice per week for 14 weeks)
Trial: 39449979
Drug: CC-CLEAR scale
RxNorm normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-CLEAR scale
Trial: 39450683
Drug: Stapokibart 300
RxNorm normalized name: Stapokibart
DrugBank: Stapokibart (DB18990)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stapokibart 300 mg every 2 weeks
Trial: 39450683
Drug: Switching from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching from placebo to stapokibart 300 mg every 2 weeks
Trial: 39450752
Drug: Microvascular inflammation
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microvascular inflammation without evidence of an antibody-mediated response
Trial: 39450752
Drug: Antibody-mediated rejection
RxNorm normalized name: digoxin antibodies Fab fragments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibody-mediated rejection
Trial: 39450752
Drug: Probable antibody-mediated
RxNorm normalized name: digoxin antibodies Fab fragments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probable antibody-mediated rejection
Trial: 39450934
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy (6 weekly individual sessions)
Trial: 39450934
Drug: Social attention
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Social attention control (6 weekly sessions)
Trial: 39453356
Drug: Survodutide, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Survodutide, a dual glucagon and GLP-1 receptor agonist, administered subcutaneously once weekly
Trial: 39453400
Drug: PLLA-SCA (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLLA-SCA (8 mL of sterile water + 1 mL of 2% lidocaine)
Trial: 39453705
Drug: PSP Wellbeing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSP Wellbeing Course (Internet-delivered cognitive behavioral therapy)
Trial: 39453772
Drug: Iptacopan (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iptacopan (200 mg) twice daily for 24 months
Trial: 39453950
Drug: Childhood Early
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Childhood Early Oral Aging Syndrome (CEOAS) index for the primary dentition
Trial: 39454227
Drug: Enzalutamide 160
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide 160 mg once daily
Trial: 39454281
Drug: IM cohort
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM cohort 1c (25/25/50 mg/m2 MWF)
Trial: 39454281
Drug: IV cohort
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV cohort (25/25/50 mg/m2 MWF)
Trial: 39455065
Drug: Filgotinib 200
RxNorm normalized name: nilotinib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filgotinib 200 mg (de novo)
Trial: 39455065
Drug: Filgotinib 100
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Filgotinib 100 mg (de novo)
Trial: 39455065
Drug: Filgotinib 200
RxNorm normalized name: nilotinib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filgotinib 200 mg (continued)
Trial: 39455065
Drug: Filgotinib 100
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Filgotinib 100 mg (continued)
Trial: 39456544
Drug: Empiric intravenous
RxNorm normalized name: aspirin / codeine phosphate Oral Tablet [Empirin with Codeine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empiric intravenous broad-spectrum antibiotics (IVBSA) for at least 48 h with PCT monitoring
Trial: 39456544
Drug: PCT drop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCT drop (defined as a reduction of 30% from baseline or a PCT level < 0.25 ng/mL)
Trial: 39458142
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard IVF treatment)
Trial: 39458156
Drug: Virtual Reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual Reality treatment
Trial: 39458438
Drug: Caffeine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (2.5 mg/kg) administered twice during continuous wakefulness, last treatment 6.5 h before bedtime for recovery night.
Trial: 39458438
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered twice during continuous wakefulness, last treatment 6.5 h before bedtime for recovery night.
Trial: 39460719
Drug: Subcutaneous ocrelizumab
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subcutaneous ocrelizumab (up to 1200 mg)
Trial: 39460719
Drug: Subcutaneous ocrelizumab
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subcutaneous ocrelizumab (920 mg)
Trial: 39460719
Drug: Intravenous ocrelizumab
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous ocrelizumab (600 mg)
Trial: 39461299
Drug: Apraglutide (once-weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apraglutide (once-weekly subcutaneous injections)
Trial: 39461302
Drug: MVA-BN-RSV vaccine
RxNorm normalized name: MVA-BN
DrugBank: Modified vaccinia ankara (DB15483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVA-BN-RSV vaccine
Trial: 39461739
Drug: Single-capsule BQT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-capsule BQT containing bismuth, metronidazole, tetracycline, and a proton pump inhibitor (PPI)
Trial: 39461739
Drug: 10-day Single-capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day Single-capsule BQT (ScBQT)
Trial: 39461739
Drug: 14-day BQT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day BQT using tetracycline plus metronidazole or amoxicillin plus either clarithromycin or metronidazole
Trial: 39461792
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (1 g by slow intravenous injection within 15 min of umbilical cord clamping)
Trial: 39461792
Drug: Placebo (matching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matching placebo by slow intravenous injection within 15 min of umbilical cord clamping)
Trial: 39461860
Drug: Photobiomodulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation therapy (three times per week using a diode laser device, starting on the first day of conditioning and continuing through day 3 post-transplant)
Trial: 39461861
Drug: Inhaled isoflurane
RxNorm normalized name: isoflurane Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled isoflurane delivered via the Sedaconda ACD-S
Trial: 39461864
Drug: Bosutinib 200
RxNorm normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bosutinib 200 mg QD for 24 weeks
Trial: 39461864
Drug: Bosutinib 300
RxNorm normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bosutinib 300 mg QD for 24 weeks
Trial: 39461878
Drug: AdAPT-001 plus
RxNorm normalized name: menthol 0.001 MG/MG [Lysine Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AdAPT-001 plus a checkpoint inhibitor (CI)
Trial: 39461878
Drug: Checkpoint inhibitor
RxNorm normalized name: Anti-tim3 checkpoint inhibitor mbg453
DrugBank: Sabatolimab (DB16322)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Checkpoint inhibitor (CI)
Trial: 39462122
Drug: Children with
RxNorm normalized name: Pediaclear Childrens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children with major alleles for SNP rs864537A > G in CD247 (AA genotype) born March-August
Trial: 39462310
Drug: Selective Endothelin
RxNorm normalized name: endothelial growth factor A, vascular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective Endothelin Receptor Antagonist SC0062
Trial: 39462354
Drug: Telephone coaching
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone coaching (5 monthly calls from physiotherapist)
Trial: 39462517
Drug: MBA-P01 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MBA-P01 (20 U, five treatments over 16 months)
Trial: 39462835
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy + short course of carbon ion radiotherapy (CIRT) followed by surgery and adjuvant chemotherapy
Trial: 39463173
Drug: Vortioxetine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine (10 or 20 mg/day)
Trial: 39463395
Drug: Sublingual microcirculatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual microcirculatory assessment on admission
Trial: 39463748
Drug: Abemaciclib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abemaciclib (150 mg twice daily for 2 years) plus endocrine therapy (ET)
Trial: 39464181
Drug: Low-dose radiation
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose radiation (150 mGy 2x/week for 5 consecutive weeks)
Trial: 39465217
Drug: Pritumumab (16.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pritumumab (16.2 mg/kg weekly)
Trial: 39465257
Drug: Neoadjuvant sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant sintilimab (200 mg, day 1), anlotinib (10 mg, QD, PO, days 1-14), and platinum-based chemotherapy for 3 cycles, followed by adjuvant sintilimab (200 mg every 3 weeks).
Trial: 39465257
Drug: Neoadjuvant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant treatment phase.